

1 SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy

2
3 Gregory E. Edelstein* B.A.,¹ Julie Boucau* Ph.D.,² Rockib Uddin B.S.,³ Caitlin Marino B.S.,²
4 May Y. Liew B.A.,³ Mamadou Barry M.D.,³ Manish C. Choudhary Ph.D.,^{1,5} Rebecca F. Gilbert
5 B.A.,³ Zahra Reynolds M.P.H.,³ Yijia Li M.D.,^{1,3,4} Dessie Tien B.S.A.,³ Shruti Sagar B.A.,³
6 Tammy D. Vyas B.S.,³ Yumeko Kawano M.D.,¹ Jeffrey A. Sparks M.D. M.Msc.,¹ Sarah P.
7 Hammond M.D.,³ Zachary Wallace M.D. M.Sc.,³ Jatin M. Vyas M.D. Ph.D.,^{3,5} Amy K.
8 Barczak^ M.D.,^{2,3,5} Jacob E. Lemieux^ M.D. D.Phil.,^{3,5,6} Jonathan Z. Li^ M.D. M.Msc.,^{1,5} and
9 Mark J. Siedner^ M.D. M.P.H.^{3,5}

10
11 *Equal contributions

12 ^Equal contributions

13 14 **Affiliations:**

15 ¹Brigham and Women's Hospital, Boston, MA, USA

16 ²Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

17 ³Massachusetts General Hospital, Boston, MA, USA

18 ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, USA

19 ⁵Harvard Medical School, Boston, MA, USA

20 ⁶Broad Institute, Cambridge, MA, USA

21 22 **Corresponding author:**

23 Mark J. Siedner, MD MPH

24 Medical Practice Evaluation Center, Massachusetts General Hospital

25 100 Cambridge Street, Suite 1600

26 Boston, MA 02114

27 msiedner@mgh.harvard.edu; +1-617-726-4686

28 29 **Funding:**

30 This work was supported by the National Institutes of Health (U19 AI110818), the
31 Massachusetts Consortium for Pathogen Readiness SARS-CoV-2 Variants Program and the
32 MGH Department of Medicine. Additional support was provided by the Ragon Institute BSL3
33 core, which is supported by the NIH-funded Harvard University Center for AIDS Research (P30
34 AI060354). Drs. Sparks and Wallace are supported by the National Institute of Arthritis and
35 Musculoskeletal and Skin Diseases (R01 AR080659). Dr. Sparks is also supported by the Llura
36 Gund Award for Rheumatoid Arthritis Research and Care. The funders had no role in study
37 design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; or
38 in the decision to submit the manuscript for publication.

39 40 **Disclaimer:**

41 The contents of this publication are solely the responsibility of the authors and do not necessarily
42 represent the official views of the National Institutes of Health.

47 **Disclosures:**

48 AKB reports consulting for ICON Government and Public Health Solutions. JZL reports
49 consulting for Abbvie and research funding from Merck. SPH reports research funding from
50 GlaxoSmithKline and has served on an advisory board for Pfizer.

51

52 **Word Count:**

53 1197

54 **Abstract**

55 Objective: To compare the frequency of replication-competent virologic rebound with and
56 without nirmatrelvir-ritonavir treatment for acute COVID-19. Secondary aims were to estimate
57 the validity of symptoms to detect rebound and the incidence of emergent nirmatrelvir-resistance
58 mutations after rebound.

59 Design: Observational cohort study.

60 Setting: Multicenter healthcare system in Boston, Massachusetts.

61 Participants: We enrolled ambulatory adults with a positive COVID-19 test and/or a prescription
62 for nirmatrelvir-ritonavir.

63 Exposures: Receipt of 5 days of nirmatrelvir-ritonavir treatment versus no COVID-19 therapy.

64 Main Outcome and Measures: The primary outcome was COVID-19 virologic rebound, defined
65 as either (1) a positive SARS-CoV-2 viral culture following a prior negative culture or (2) two
66 consecutive viral loads ≥ 4.0 log₁₀ copies/milliliter after a prior reduction in viral load to < 4.0
67 log₁₀ copies/milliliter.

68 Results: Compared with untreated individuals (n=55), those taking nirmatrelvir-ritonavir (n=72)
69 were older, received more COVID-19 vaccinations, and were more commonly
70 immunosuppressed. Fifteen individuals (20.8%) taking nirmatrelvir-ritonavir experienced
71 virologic rebound versus one (1.8%) of the untreated (absolute difference 19.0% [95%CI 9.0-
72 29.0%], P=0.001). In multivariable models, only N-R was associated with VR (AOR 10.02,
73 95%CI 1.13-88.74). VR occurred more commonly among those with earlier nirmatrelvir-
74 ritonavir initiation (29.0%, 16.7% and 0% when initiated days 0, 1, and ≥ 2 after diagnosis,
75 respectively, P=0.089). Among participants on N-R, those experiencing rebound had prolonged
76 shedding of replication-competent virus compared to those that did not rebound (median: 14 vs 3
77 days). Only 8/16 with virologic rebound reported worsening symptoms (50%, 95%CI 25%-
78 75%); 2 were completely asymptomatic. We detected no post-rebound nirmatrelvir-resistance
79 mutations in the NSP5 protease gene.

80 Conclusions and Relevance: Virologic rebound occurred in approximately one in five people
81 taking nirmatrelvir-ritonavir and often occurred without worsening symptoms. Because it is
82 associated with replication-competent viral shedding, close monitoring and potential isolation of
83 those who rebound should be considered.

84

85

86 **Introduction**

87 Data are conflicting about whether nirmatrelvir-ritonavir (N-R) is associated with virologic
88 rebound (VR).¹⁻⁷ However, precise estimation of VR incidence with and without N-R use has
89 been limited by infrequent and short-term sampling, symptomatic reporting, and absence of
90 culture data.

91

92 **Methods**

93 The Post-vaccination Viral Characteristics Study (POSITIVES) is a prospective, observational
94 cohort of individuals with acute COVID-19 with longitudinal sampling for viral load, viral
95 culture, and symptom reporting (**supplementary appendix**).^{8,9} Participants are sampled from
96 automated medical record reports in the Mass General Brigham healthcare system on individuals
97 with positive testing or a prescription for COVID-19 therapeutics.

98

99 Participants self-collect anterior nasal swabs three times a week for two weeks and weekly
100 thereafter until SARS-CoV-2 viral load testing is persistently undetectable. Specimens are
101 analyzed for SARS-CoV-2 viral load, viral culture, and whole genome sequencing. Participants
102 complete 10-item COVID-19 symptom surveys, graded as absent (0), mild (1), moderate (2), or
103 severe (3), for a maximum total symptom score (TSS) of 30-points. Study physicians complete
104 chart reviews to determine COVID-19 vaccination and treatment history, and
105 immunosuppression status (**STable1**).

106

107 We sought to estimate the incidence of virologic rebound, which we defined in individuals with
108 either 1) positive SARS-CoV-2 viral culture following a negative culture or 2) a viral load ≥ 1.0
109 \log_{10} from a prior viral load and $\geq 4.0 \log_{10}$ copies/mL for two consecutive timepoints after a

110 prior reduction in viral load to $<4.0 \log_{10}$ copies/mL. We selected this outcome as a surrogate for
111 putative transmission risk, based on data relating transmission to replication-competent virus
112 with viral loads $>4.0 \log_{10}$ copies/mL.^{10,11} For a secondary outcome, we redefined VR as a viral
113 load at days 10 and 14 $\geq 2.7 \log_{10}$ and at least $0.5 \log_{10}$ greater than the result at day 5, in order to
114 compare our estimates to the EPIC-HR study, which considered fewer time points and did not
115 incorporate culture methods.¹

116
117 Our primary exposure of interest was exposure to N-R therapy. Therefore, we limited analysis to
118 ambulatory participants enrolled after March 2022, when we began recruiting individuals
119 initiating N-R. We also excluded participants without a nasal swab collected >11 days from their
120 first positive COVID-19 test, because approximately 90% of rebound phenomena occur by this
121 time,⁸ and individuals who received N-R for more or less than 5 days. We compared the
122 frequency of VR by N-R use overall and stratified by potential confounders (i.e.,
123 immunosuppression, age, sex, and prior COVID-19 vaccinations) using two-sided Fisher's exact
124 tests, and after adjustment for confounders, in logistic regression models. We compared the
125 frequency of VR by timing of N-R initiation, using a non-parametric test of trend. We compared
126 our estimate of VR with the definition used in the EPIC-HR study.¹ We used the Kaplan-Meier
127 survival estimator to depict and compare days to initial and final viral culture negativity,
128 stratified by N-R use and VR, using log-rank testing. We assessed the validity of symptom
129 rebound, as defined by an increase in TSS by 3 or more points from a prior date, and the
130 presence of any symptoms during the rebound period, to detect VR.⁶ Finally, we report the
131 proportion of sequenced viruses before and after VR with mutations in the NSP5 gene encoding

132 the main protease (M^{Pro}) of SARS-CoV-2. Statistical analyses and figure production were
133 conducted with Stata version 16.1 and GraphPad Prism version 9.5.

134

135 *Ethical Considerations*

136 All study participants provided verbal informed consent. Written consent was waived by the
137 ethics committee, based on the involvement of participants with acute COVID-19 in a minimal
138 risk study. The study procedures were approved by Institutional Review Board and the
139 Institutional Biosafety Committee at Mass General Brigham.

140

141 **Results**

142 Compared with untreated individuals (n=55), those taking N-R (n=72) were older (57 vs 39
143 years, P<0.001), received more COVID-19 vaccinations (median 4 vs 3, P<0.001) and were
144 more commonly immunosuppressed (32% vs 9%, P<0.001, **SFig1/STable2**). Fifteen individuals
145 (20.8%) taking N-R experienced VR versus one (1.8%) untreated individual (**Figures 1&2**,
146 absolute difference 19.0% [95% CI 9.0-29.0%], P=0.001). In sub-group analyses, VR was
147 numerically more frequent in all demographic and clinical sub-groups (**Figure 2**). In
148 multivariable logistic regression models including demographic and clinical characteristics, only
149 N-R use remained associated with VR (**STable 3**). There was a trend towards higher rates of VR
150 with earlier N-R initiation (29%, 16.7% and 0% when initiated days 0, 1, and ≥ 2 after diagnosis,
151 P=0.089, **Figure 2**). When we restricted analyses to three timepoints, as done in the EPIC-HR
152 study, only 3/124 (2.4%) had rebound detected, and 13/16 (81.2%) rebound events were not
153 captured (**Figure 1E-F**). We detected no post-N-R drug resistance mutations in the NSP5
154 protease gene (**SFig2**).

155
156 N-R recipients achieved initial culture conversion sooner than those not treated (**Figure**
157 **3/STable4**, $P < 0.001$). However, days to final culture conversion was similar (**Figure 3**, $P = 0.29$)
158 because those experiencing VR had significantly prolonged shedding (median 14 [IQR13-20] vs
159 3 days [IQR2-4], **Figure 3/STable4/STable5**). Only 8/16 with VR reported symptom rebound
160 (50%, 95% CI 25-75%); 2 were totally asymptomatic. Only 8/27 with symptom rebound had VR
161 (30%, 95% CI 14-50%, **SFig3/STable6**).

162
163 **Discussion**

164 VR with replication-competent viral shedding occurred in approximately 20% of those taking N-
165 R and 2% of those not on therapy. N-R use remained associated with VR after adjustment for
166 demographic and clinical characteristics, such as vaccination and immunosuppression status.
167 Although N-R treated individuals took fewer days to achieve initial culture negativity, time to
168 final culture negativity was similar, due to prolonged shedding of replication-competent virus
169 among those experiencing VR (median 14 vs 3 days). These data support the presence of an N-
170 R-associated virologic rebound phenomenon, which substantially increases the duration of
171 shedding of replication-competent virus and has implications for post-N-R monitoring and
172 isolation recommendations.

173
174 We found a higher incidence of VR with N-R use than prior studies. We believe this is due to use
175 of frequent sampling and culture methods to detect VR. When we restricted our analysis to three
176 PCR-based timepoints, as done in prior trials,¹ we detected a 2.4% rate of VR, which
177 approximates prior studies, but notably missed 80% of VR events.

178
179 VR appeared to be less common among those who delayed therapy by 1 or 2 days after their first
180 positive test. This finding, in conjunction with the lack of drug resistance-associated mutations
181 after VR events, promotes hypotheses that VR may occur due to incomplete viral eradication,¹²
182 and supports studies to evaluate longer durations of N-R therapy.¹³

183
184 Finally, symptoms should not be relied upon to detect or exclude VR. Two individuals with VR
185 had a complete absence of symptoms during the VR period and less than half had symptom
186 rebound. Conversely, the majority of those who did have symptom rebound did not experience
187 VR.

188
189 Our study was limited by an observational design, with expected differences between those
190 taking N-R and untreated individuals based on treatment guidelines for N-R¹⁴. Nonetheless, VR
191 remained associated with N-R, even after adjustment for potential confounders. We used viral
192 culture as a surrogate for transmission risk but did not measure contagiousness or transmission
193 events directly.


194
195 These data support a relationship between N-R use and VR. Future work should elucidate the
196 mechanistic pathways of VR, determine if delays in initiating N-R or longer courses of N-R may
197 prevent VR among high-risk individuals, and evaluate larger samples to identify the risk factors
198 for N-R-associated VR.

199 **Acknowledgments**


200 We would like to thank the study participants for their time and considerable efforts to provide
201 specimens in the acute phase of illness as part of this project.

202

203 **Figure 1.** Virologic decay curves with semiquantitative viral cultures and quantitative viral load
204 among individuals with acute COVID-19 taking no therapy or nirmatrelvir-ritonavir (N-R).
205 Black lines indicate individuals without rebound, whereas blue lines indicate individuals with
206 virologic rebound. Panels A (viral load) and B (viral culture) depict decay curves for those not
207 receiving therapy. Panels C (viral load) and D (viral culture) depict individuals who received N-
208 R. Panels E and F compare our primary outcome with all available time points (E) or restricted to
209 days 5, 10 and 14 only (Panel F) as defined in prior studies [1]. Using only three timepoints to
210 detect rebound resulted in missing 81% of the observed virologic rebound events of replication-
211 competent virus.




213 **Figure 2.** Comparative frequency of virologic rebound by nirmatrelvir-ritonavir use, stratified by demographics and clinical
 214 characteristics (A), and by number of days between the first positive SARS-CoV-2 test and initiation of nirmatrelvir-ritonavir therapy
 215 (B). For the sub-group comparisons, the bottom P-values represent Fisher's exact tests comparing rebound rates between those taking
 216 versus those not taking nirmatrelvir-ritonavir. The upper P-values represent Fisher's exact tests comparing rebound rates among those
 217 taking nirmatrelvir-ritonavir across the sub-groups, for example comparing those taking nirmatrelvir-ritonavir with
 218 immunosuppression present versus those taking nirmatrelvir-ritonavir with immunosuppression absent.




221 **Figure 3.** Kaplan Meier survival curves demonstrating time from initial positive SARS-CoV-2 test until initial negative viral culture
 222 (A-C) and final negative culture (D-F). In Panel A, we demonstrate that there is a faster time to first negative culture in those receiving
 223 nirmatrelvir-ritonavir (N-R) versus no therapy (No Rx). In Panels B and C, we find similar patterns in time to initial negative culture,
 224 when dividing the N-R group into those who rebounded (B) and those who did not (C). However, as shown in Panel D, there is no
 225 difference in time to final negative culture between N-R and No Rx groups. This appears to be due to the prolonged time to final
 226 negative culture among N-R users who rebound (Panel E), because the time to final negative culture remains shorter in N-R users who
 227 did not rebound compared to the No Rx group (Panel F).

Time to Initial Negative Culture (A-C)



Time to Final Negative Culture (D-F)



242 ns: non-significant; **: $P < 0.01$; ****: $P < 0.0001$

243 **REFERENCES CITED**

- 244 1. Anderson AS, Caubel P, Rusnak JM. Nirmatrelvir–ritonavir and viral load rebound in
245 COVID-19. *New England Journal of Medicine*. 2022;387(11):1047-1049.
- 246 2. Charness ME, Gupta K, Stack G, et al. Rebound of SARS-CoV-2 Infection after
247 Nirmatrelvir-Ritonavir Treatment. *N Engl J Med*. 2022;387(11):1045-1047.
248 doi:10.1056/NEJMc2206449
- 249 3. Epling BP, Rocco JM, Boswell KL, et al. Clinical, Virologic, and Immunologic Evaluation
250 of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir
251 Treatment. *Clin Infect Dis*. 2023;76(4):573-581. doi:10.1093/cid/ciac663
- 252 4. Pandit JA, Radin JM, Chiang D, et al. The COVID-19 Rebound Study: A Prospective Cohort
253 Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated with
254 Nirmatrelvir Plus Ritonavir Versus Untreated Controls. *Clin Infect Dis*. Published online
255 February 22, 2023:ciad102. doi:10.1093/cid/ciad102
- 256 5. Wong GLH, Yip TCF, Lai MSM, Wong VWS, Hui DSC, Lui GCY. Incidence of Viral
257 Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir. *JAMA Netw Open*.
258 2022;5(12):e2245086. doi:10.1001/jamanetworkopen.2022.45086
- 259 6. Deo R, Choudhary MC, Moser C, et al. Symptom and Viral Rebound in Untreated SARS-
260 CoV-2 Infection. *Ann Intern Med*. 2023;176(3):348-354. doi:10.7326/M22-2381
- 261 7. Wong CKH, Lau KTK, Au ICH, et al. Viral burden rebound in hospitalised patients with
262 COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort
263 study. *Lancet Infect Dis*. Published online February 13, 2023:S1473-3099(22)00873-8.
264 doi:10.1016/S1473-3099(22)00873-8
- 265 8. Boucau J, Uddin R, Marino C, et al. Characterization of Virologic Rebound Following
266 Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19). *Clin Infect*
267 *Dis*. 2023;76(3):e526-e529. doi:10.1093/cid/ciac512
- 268 9. North CM, Barczak A, Goldstein RH, et al. Determining the Incidence of Asymptomatic
269 SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19):
270 A Prospective Cohort Study of Healthcare Workers Before, During and After Vaccination.
271 *Clin Infect Dis*. 2022;74(7):1275-1278. doi:10.1093/cid/ciab643
- 272 10. Goyal A, Reeves DB, Cardozo-Ojeda EF, Schiffer JT, Mayer BT. Viral load and contact
273 heterogeneity predict SARS-CoV-2 transmission and super-spreading events. Walczak AM,
274 Childs L, Forde J, eds. *eLife*. 2021;10:e63537. doi:10.7554/eLife.63537
- 275 11. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients
276 with COVID-2019. *Nature*. 2020;581(7809):465-469. doi:10.1038/s41586-020-2196-x
- 277 12. Perelson AS, Ribeiro RM, Phan T. *An Explanation for SARS-CoV-2 Rebound after Paxlovid*
278 *Treatment*. *Infectious Diseases (except HIV/AIDS)*; 2023. doi:10.1101/2023.05.30.23290747

- 279 13. National Institutes of Health. A Study to Learn About the Study Medicines (Nirmatrelvir
280 Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised
281 Immune System (NCT05438602). Published April 11, 2023. Accessed April 20, 2023.
282 <https://clinicaltrials.gov/ct2/show/NCT05438602>
- 283 14. National Institutes of Health. Therapeutic Management of Nonhospitalized Adults With
284 COVID-19. COVID-19 Treatment Guidelines. Published April 20, 2023. Accessed April 21,
285 2023. [https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-](https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/)
286 [of-adults/nonhospitalized-adults--therapeutic-management/](https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/)
- 287
- 288